Adant has a narrow registered footprint, available in five countries — primarily across a regional spread that includes Japan, Indonesia, Malaysia, Turkey, and Egypt. The brand has not been broadly internationalised, and a traveller arriving in Europe, the Americas, or much of Africa is unlikely to find Adant under this specific name on a pharmacy shelf or in a hospital formulary.
The active ingredient in Adant is sodium hyaluronate. Across the indications recognised in the markets where it is registered, sodium hyaluronate is used as an adjunct in ophthalmic surgical procedures — including cataract extraction, corneal transplantation, and procedures associated with glaucoma — and is also classified within categories relating to analgesic, anti-inflammatory, and musculoskeletal-tissue support. The structured indication section further down this page sets out the registered uses in detail.
Outside the cluster of countries where Adant is sold, sodium hyaluronate itself is widely available under a variety of other brand names and formulations. A patient or clinician familiar with Adant from one of its core markets will generally find a comparable sodium-hyaluronate product in the destination country, though it is likely to carry a different brand name and may be presented in a different formulation or device.
A local pharmacist, ophthalmologist, or musculoskeletal specialist familiar with the regional formulary is the right person to identify the appropriate equivalent. Decisions about substitution — particularly in surgical or specialist contexts — belong with the treating healthcare provider, who can weigh the specific formulation, indication, and clinical circumstances involved.
No information provided.
At present there are no known contraindications to the use of the Adant OVD when used as recommended.
The Adant OVD is extremely well tolerated after injection into human eyes. A transient rise of intraocular pressure postoperatively has been reported in some cases.
In posterior segment surgery intraocular pressure rises have been reported in some patients, especially in aphakic diabetics, after injection of large amounts of the Adant OVD.
Rarely, postoperative inflammatory reactions (iritis, hypopyon) as well as incidents of corneal edema and corneal decompensation have been reported. Their relationship to the Adant OVD has not been established.
The Adant OVD is indicated for use as a surgical aid in cataract extraction (intra- and extracapsular), IOL implantation, corneal transplant, glaucoma filtration and retinal attachment surgery.
In surgical procedures in the anterior segment of the eye, instillation of the Adant OVD serves to maintain a deep anterior chamber during surgery, allowing for efficient manipulation with less trauma to the corneal endothelium and other surrounding tissues.
Furthermore, its viscoelasticity helps to push back the vitreous face and prevent formation of a postoperative flat chamber.
In posterior segment surgery the Adant OVD serves as a surgical aid to gently separate, maneuver and hold tissues.The Adant OVD creates a clear field of vision thereby facilitating intra- and post-operative inspection of the retina and photocoagulation.
Included as part of the PRECAUTIONS section.
PRECAUTIONSThose normally associated with the surgical procedure being performed.
Overfilling the anterior or posterior segment of the eye with the Adant OVD may cause increased intraocular pressure, glaucoma, or other ocular damage.
Postoperative intraocular pressure may also be elevated as a result of preexisting glaucoma, compromised outflow and by operative procedures and sequelae thereto, including enzymatic zonulysis, absence of an iridectomy, trauma to filtration structures, and by blood and lenticular remnants in the anterior chamber. Since the exact role of these factors is difficult to predict in any individual case, the following precautions are recommended:
Care should be taken to avoid trapping air bubbles behind the Adant OVD.
Because the Adant OVD is a highly purified fraction extracted from avian tissues and is known to contain minute amounts of protein, the physician should be aware of potential risks of the type that can occur with the injection of any biological material.
Because of reports of an occasional release of minute rubber particles, presumably formed when the diaphragm is punctured, the physician should be aware of this potential problem. Express a small amount of the Adant OVD from the syringe prior to use, and carefully examine the remainder as it is injected.
Reprocessed cannulas should not be used.
Sporadic reports have been received indicating that the Adant OVD may become ”cloudy” or form a slight precipitate following instillation into the eye.The clinical significance of these reports, if any, is not known since the majority received to date do not indicate any harmful effects on ocular tissues.The physician should be aware of this phenomenon and, should it be observed, remove the cloudy or precipitated material by irrigation and/or aspiration.
In vitro laboratory studies suggest that this phenomenon may be related to interactions with certain concomitantly administered ophthalmic medications.
Use only if solution is clear.
A sufficient amount of the Adant OVD is slowly, and carefully introduced (using a cannula or needle) into the anterior chamber.
Injection of the Adant OVD can be performed either before or after delivery of the lens. Injection prior to lens delivery will, however, have the additional advantage of protecting the corneal endothelium from possible damage arising from the removal of the cataractous lens5.The Adant OVD may also be used to coat surgical instruments and the IOL prior to insertion.
Additional Adant OVD can be injected during surgery to replace any Adant OVD lost during surgical manipulation (see PRECAUTIONS section).
Glaucoma Filtration SurgeryIn conjunction with performing of the trabeculectomy, the Adant OVD is injected slowly and carefully through a corneal paracentesis to reconstitute the anterior chamber. Further injection of the Adant OVD can be continued allowing it to extrude into the subconjunctival filtration site and through and around the sutured outer scleral flap.
Corneal Transplant SurgeryAfter removal of the corneal button, the anterior chamber is filled with the Adant OVD.The donor graft can then be placed on top of the bed of Adant OVD and sutured in place.Additional Adant OVD may be injected to replace the Adant OVD lost as a result of surgical manipulation (see PRECAUTIONS section).The Adant OVD has also been used in the anterior chamber of the donor eye prior to trepanation to protect the corneal endothelial cells of the graft5.
Retinal Attachment SurgeryThe Adant OVD is slowly introduced into the vitreous cavity. By directing the injection, the Adant OVD can be used to separate membranes (e.g. epiretinal membranes) away from the retina for safe excision and release of traction.The Adant OVD also serves to maneuver tissues into the desired position, e.g. to gently push back a detached retina or unroll a retinal flap, and aids in holding the retina against the sclera for reattachment.
Instructions Sterile Opening TechniqueTear off the paper covering.
Bend the plastic backwards at the central indentation so as to fully expose the white plastic rod.
Dislodge syringe and place onto sterile field.
Press the vial completely into the holder so that the needle perforates the membrane.
ImportantPerforate the membrane before screwing on the plastic rod.
Remove the plastic rod.
Screw the plastic rod into the blue plunger.
Connect the cannula and check for proper function.
Store at 2 to 8°C (36 to 46°F). For single use only
Adant is used in contexts associated with ophthalmic surgical procedures — including cataract extraction, corneal transplantation, and glaucoma surgery — as well as in the management of certain musculoskeletal conditions where sodium hyaluronate is indicated. The structured indication block lower down on this page lists the registered uses recognised by national regulators in the markets where Adant is sold.
Adant contains sodium hyaluronate, a substance classified across analgesic, anti-inflammatory, and musculoskeletal-tissue categories depending on the indication and formulation. Sodium hyaluronate is used internationally under a number of different brand names and across several formulations, particularly within ophthalmic surgery and joint-related musculoskeletal therapy.
Adant is registered in five countries: Japan, Indonesia, Malaysia, Turkey, and Egypt. The brand has a relatively narrow registered footprint and is unlikely to be encountered outside this cluster. Sodium hyaluronate itself, however, is available in many additional markets under different commercial names — a local pharmacist can confirm whether an equivalent product is sold in your country.
Sodium hyaluronate is marketed under a range of brand names worldwide, both as ophthalmic surgical adjuncts and as intra-articular preparations within the broader musculoskeletal category. Other products addressing similar therapeutic roles also exist, although they are not freely interchangeable. To identify a regional equivalent, search the active ingredient on Pill2Trip or ask a pharmacist or specialist familiar with the local formulary.
Yes. Sodium hyaluronate products are generally administered or prescribed in a clinical setting, particularly in ophthalmic surgery and specialist musculoskeletal care, and prescription rules differ considerably between countries. Travellers and patients relocating between markets should rely on a healthcare provider — and where relevant a surgeon or specialist — to coordinate continuity of care rather than attempting to substitute the product independently.
